Advertisement
Singapore markets close in 22 minutes
  • Straits Times Index

    3,287.16
    -5.97 (-0.18%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE 100

    8,095.59
    +55.21 (+0.69%)
     
  • Bitcoin USD

    63,888.88
    -2,823.65 (-4.23%)
     
  • CMC Crypto 200

    1,365.91
    -16.66 (-1.21%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,337.50
    -0.90 (-0.04%)
     
  • Crude Oil

    83.23
    +0.42 (+0.51%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,570.51
    -0.97 (-0.06%)
     
  • Jakarta Composite Index

    7,156.81
    -17.73 (-0.25%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Is Biogen a Buy After the Latest Aduhelm Disaster?

Is Biogen a Buy After the Latest Aduhelm Disaster?

Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.